曲霉病市场
曲霉病市场：2026年市场规模约为69.1亿美元，2031年市场规模约为88.6亿美元；预测期复合年增长率为5.12%；当前最大市场为北美；增长最快的市场为亚太地区。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 95.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
待补内容：缺少细分份额核心结论
曲霉病市场：2026年市场规模约为69.1亿美元，2031年市场规模约为88.6亿美元；预测期复合年增长率为5.12%；当前最大市场为北美；增长最快的市场为亚太地区。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 5.12% | 机构预测 |
| 市场规模 | 2026 | USD 6.91 billion | 机构预测 |
| 市场规模 | 2031 | USD 8.86 billion | 机构预测 |
主要参与者
- Pfizer Inc.
- Merck & Co., Inc.
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Cipla Limited
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Expanding Immunocompromised Patient Pool | +1.500% | Global | Long term (≥ 4 years) |
| Rising Transplantation and Hematologic Cancer Treatment Volumes | +1.000% | North America, Europe, Asia-Pacific | Medium term (2-4 years) |
| Earlier Diagnosis Through Molecular and Biomarker Testing | +0.800% | North America, Europe | Medium term (2-4 years) |
| Next-Generation Antifungal Development | +0.900% | Global | Medium term (2-4 years) |
| Growing Chronic Pulmonary Disease Burden | +0.500% | Asia-Pacific, Middle East and Africa, South America | Long term (≥ 4 years) |
| Climate-Linked Expansion of Aspergillus Exposure | +0.400% | Europe, North America, Asia-Pacific, Middle East and Africa | Long term (≥ 4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Azole Resistance and Limited Novel Drug Classes | -0.400% | Global, especially Europe and Asia-Pacific | Medium term (2-4 years) |
| High Total Cost of Therapy and Hospital Care | -0.300% | Middle East and Africa, South America, developing Asia-Pacific markets | Long term (≥ 4 years) |
| Delayed Diagnosis and Specialist Shortage | -0.200% | Middle East and Africa, South America, South and Southeast Asia | Long term (≥ 4 years) |
| Fragile Antifungal API and Specialized Test Supply Chains | -0.100% | Global, with concentration risk in Asia-Pacific and Middle East and Africa | Short term (≤ 2 years) |
报告关注的关键问题
What is the expected growth rate for aspergillosis treatment demand?
The aspergillosis market is forecast to grow at a 5.1% CAGR from 2026 to 2031, rising from USD 6.91 billion in 2026 to USD 8.86 billion in 2031. Demand is linked to immunocompromised patients, chronic respiratory disease, transplantation, and the need for treatments that manage resistant infections safely.
Which aspergillosis type is growing fastest?
Invasive aspergillosis is forecast to grow at a 5.5% CAGR through 2031. Its treatment demand is closely connected to allogeneic transplantation, hematologic cancer care, intensive care units, and the need for protocol-based prophylaxis and rescue therapy.
Which drug class leads treatment spending?
Azoles held 58.6% share in 2025, reflecting their established role in oral treatment and prophylaxis. Echinocandins are forecast to grow at a 5.6% CAGR through 2031 as long-acting development and combination treatment evidence expand their relevance in high-acuity care.
Why is azole resistance important for treatment planning?
Resistance can reduce the reliability of first-line azoles and increase the need for susceptibility testing, combination therapy, and novel agents. It is especially relevant in Europe, where surveillance has identified substantial resistant isolate rates in the Netherlands and Belgium.
Which region is expected to expand fastest?
Asia-Pacific is forecast to grow at a 5.8% CAGR through 2031. Growth reflects chronic pulmonary aspergillosis associated with prior tuberculosis, expanding transplantation capacity, and improving access to specialized antifungal care in major regional markets.
What are the main new antifungal programs to watch?
Olorofim, fosmanogepix, rezafungin, and inhaled itraconazole programs represent important development activity across invasive, prophylactic, and allergic disease settings. Their progress matters because resistance, toxicity, and long treatment duration continue to limit current care choices for clinicians and patients.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence